{"id":496697,"date":"2020-07-17T12:26:01","date_gmt":"2020-07-17T12:26:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=496697"},"modified":"2020-07-17T12:26:01","modified_gmt":"2020-07-17T12:26:01","slug":"sjogrens-syndrome-pipeline-insights-2020","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/sjogrens-syndrome-pipeline-insights-2020_496697.html","title":{"rendered":"Sjogren&#8217;s Syndrome Pipeline Insights, 2020"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Sjogren&#039;s Syndrome Pipeline Insights, 2020\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Sjogren&#039;s Syndrome Pipeline Insights, 2020\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">Sjogren&#8217;s Syndrome Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Sjogren&#8217;s Syndrome market. A detailed picture of the Sjogren&#8217;s Syndrome pipeline landscape is provided, which includes the disease overview and Sjogren&#8217;s Syndrome treatment guidelines.<\/div>\n<p style=\"text-align: justify;\"><strong>Sjogren&#8217;s Syndrome of pipeline development activities <\/strong><\/p>\n<p style=\"text-align: justify;\">The report provides insights into:&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>All of the companies that are developing therapies for the treatment of&nbsp;Sjogren&#8217;s Syndrome&nbsp;with aggregate therapies developed by each company for the same.<\/li>\n<li>Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the&nbsp;Sjogren&#8217;s Syndrome&nbsp;treatment.<\/li>\n<li>Sjogren&#8217;s Syndrome&nbsp;key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/li>\n<li>Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/sjogrens-syndrome-pipeline-insight\" target=\"_blank\">Scope of Sjogren&#8217;s Syndrome Report<\/a><\/p>\n<ul style=\"text-align: justify;\">\n<li>The&nbsp;Sjogren&#8217;s Syndrome&nbsp;report provides an overview of&nbsp;<em>therapeutic pipeline activity and therapeutic assessment of the products<\/em>&nbsp;by development stage, product type, route of administration, molecule type, and MOA type&nbsp;<em>for&nbsp;<\/em>Sjogren&#8217;s Syndrome&nbsp;across the complete product development cycle, including all clinical and nonclinical stages.<\/li>\n<li>It comprises of&nbsp;<em>detailed profiles of&nbsp;<\/em>Sjogren&#8217;s Syndrome&nbsp;<em>therapeutic products<\/em>&nbsp;with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details<\/li>\n<li>Detailed&nbsp;Sjogren&#8217;s Syndrome&nbsp;<em>research and development progress and trial details<\/em>, results wherever available, are also included in the pipeline study.<\/li>\n<li><em>Coverage of dormant and discontinued pipeline project<\/em>s along with the reasons if available across&nbsp;Sjogren&#8217;s Syndrome.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/sjogrens-syndrome-pipeline-insight\" target=\"_blank\">Request for sample pages<\/a>&nbsp;<\/p>\n<p style=\"text-align: justify;\">Several companies are working robustly on developing many new therapies, such as Belimumab (GlaxoSmithKline), RSLV-132 (Resolve Therapeutics), VAY736 (Novartis\/MorphoSys), CFZ533 (Novartis), LOU-064 (Novartis), Filgotinib (Galapagos NV \/Gilead Sciences), VIB7734 (Viela Bio), GS-9876 (Gilead Sciences), Lacripep (TearSolutions), Abatacept (Bristol Myers Squibb), RO5459072 (Roche), Immupharma and others for the treatment of Sjogren&rsquo;s syndrome. The mid-stage pipeline is crowded, with several potential therapies with the imminent attention of big pharmaceutical companies for this market space.<\/p>\n<p style=\"text-align: justify;\"> VAY736 (Ianalumab) (Novartis\/MorphoSys) is a novel, subcutaneous, defucosylated, monoclonal antibody, that targets human B cell-activating factor (BAFF). It is engineered to prevent BAFF signaling and effectively eliminate B cells from circulation in vivo by antibody-dependent cellular cytotoxicity (ADCC), providing a dual mode of action. The molecule is being developed by the Novartis in partnership with MorphoSys as an antibody-based therapy. It is currently in Phase II clinical studies for the treatment of moderate to severe Primary Sj&ouml;gren&#8217;s Syndrome. The drug has met the primary endpoint assessing ESSDAI, showing statistically significant dose-response for Ianalumab with clinically important improvement in the results presented in 2019 ACR\/ARP Annual Meeting.&nbsp;<\/p>\n<p style=\"text-align: justify;\">Along with Ianalumab, Novartis also has another two potential candidates Iscalimab and LOU-064 being under development for the treatment of Sj&ouml;gren&#8217;s Syndrome and all are having a different mechanism of actions, providing an edge to compete with others.<\/p>\n<p style=\"text-align: justify;\">Iscalimab (CFZ533) (Novartis) is a novel monoclonal antibody that potently and selectively blocks CD40, a co-stimulatory pathway involved in the activation of immune B-cells, implicated in Sj&ouml;gren&rsquo;s syndrome pathogenesis. The molecule is being studied in Phase II clinical trials with Primary Sj&ouml;gren&rsquo;s Syndrome who experience systemic manifestations of the disease. The intravenous Iscalimab experienced a mean reduction in overall disease activity of 5.2 points on the ESSDAI score and established primary efficacy and cleared the pathway for future studies.<\/p>\n<p style=\"text-align: justify;\">LOU-064 (Novartis) is being developed as novel covalent BTK inhibitor that acts as a potential therapy for B-cell-driven autoimmune diseases including Sj&ouml;gren&rsquo;s syndrome. The oral formulation showed rapid absorption, with a fast onset of action and sustained blood BTK occupancy and blood B cell inhibition. Based on these results, Novartis has started Phase II (LOUiSSe) studies for the treatment of moderate to severe Sj&ouml;gren&#8217;s Syndrome.<\/p>\n<p style=\"text-align: justify;\">Belimumab (GlaxoSmithKline) is a monoclonal antibody, designed to target and inhibit B-lymphocyte stimulator (BLyS)-specific inhibitor, which will be able to reduce B-cell mediated immunity and the autoimmune response. It has been approved for the treatment of SLE and the mechanism of action has shown to be effective in the treatment of Sj&ouml;gren&rsquo;s syndrome, as it is characterized by an increase in BAFF (BLyS) levels and resulting B cell hyperactivity. Based on this rationale, currently, GSK is evaluating.&nbsp;<\/p>\n<p style=\"text-align: justify;\">Table of contents<\/p>\n<p style=\"text-align: justify;\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Sjogren&#8217;s Syndrome&nbsp;<\/p>\n<p style=\"text-align: justify;\">2.1. Overview<\/p>\n<p style=\"text-align: justify;\">2.2. History&nbsp;<\/p>\n<p style=\"text-align: justify;\">2.3. Sjogren&#8217;s Syndrome Symptoms<\/p>\n<p style=\"text-align: justify;\">2.4. Causes<\/p>\n<p style=\"text-align: justify;\">2.5.Pathophysiology<\/p>\n<p style=\"text-align: justify;\">2.6. Sjogren&#8217;s Syndrome Diagnosis&nbsp;<\/p>\n<p style=\"text-align: justify;\">2.6.1. Diagnostic Guidelines<\/p>\n<p style=\"text-align: justify;\">3. Sjogren&#8217;s Syndrome&nbsp;Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\">3.1. Sjogren&#8217;s Syndrome Treatment Guidelines<\/p>\n<p style=\"text-align: justify;\">4. Sjogren&#8217;s Syndrome&nbsp;&#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">4.1. In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\">4.1.1. Sjogren&#8217;s Syndrome&nbsp;companies collaborations, Licensing, Acquisition -Deal Value Trends<\/p>\n<p style=\"text-align: justify;\">4.1.1.1. Assessment Summary<\/p>\n<p style=\"text-align: justify;\">4.1.2. Sjogren&#8217;s Syndrome&nbsp;Collaboration Deals<\/p>\n<p style=\"text-align: justify;\">4.1.2.1. Company-Company Collaborations (Licensing \/ Partnering) Analysis<\/p>\n<p style=\"text-align: justify;\">4.1.2.2. Company-University Collaborations (Licensing \/ Partnering) Analysis<\/p>\n<p style=\"text-align: justify;\">4.1.2.3. Sjogren&#8217;s Syndrome&nbsp;Acquisition Analysis<\/p>\n<p style=\"text-align: justify;\">5.&nbsp;Sjogren&#8217;s Syndrome&nbsp;Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">5.1. Clinical Assessment of Pipeline Drugs&nbsp;<\/p>\n<p style=\"text-align: justify;\">5.1.1. Assessment by Phase of Development<\/p>\n<p style=\"text-align: justify;\">5.1.2. Assessment by Product Type (Mono \/ Combination)<\/p>\n<p style=\"text-align: justify;\">5.1.2.1. Assessment by Stage and Product Type<\/p>\n<p style=\"text-align: justify;\">5.1.3. Assessment by Route of Administration<\/p>\n<p style=\"text-align: justify;\">5.1.3.1. Assessment by Stage and Route of Administration<\/p>\n<p style=\"text-align: justify;\">5.1.4. Assessment by Molecule Type<\/p>\n<p style=\"text-align: justify;\">5.1.4.1. Assessment by Stage and Molecule Type<\/p>\n<p style=\"text-align: justify;\">5.1.5. Assessment by MOA<\/p>\n<p style=\"text-align: justify;\">5.1.5.1. Assessment by Stage and MOA<\/p>\n<p style=\"text-align: justify;\">5.1.6. Assessment by Target<\/p>\n<p style=\"text-align: justify;\">5.1.6.1. Assessment by Stage and Target<\/p>\n<p style=\"text-align: justify;\">6. Sjogren&#8217;s Syndrome Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\">7. Sjogren&#8217;s Syndrome Mid Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\">12. Sjogren&#8217;s Syndrome Discontinued Products<\/p>\n<p style=\"text-align: justify;\">13. Sjogren&#8217;s Syndrome&nbsp;Product Profiles<\/p>\n<p style=\"text-align: justify;\">13.1. Drug Name: Company&nbsp;<\/p>\n<p style=\"text-align: justify;\">13.1.1. Product Description<\/p>\n<p style=\"text-align: justify;\">13.1.1.1. Product Overview<\/p>\n<p style=\"text-align: justify;\">13.1.1.2. Mechanism of action<\/p>\n<p style=\"text-align: justify;\">13.1.2. Research and Development<\/p>\n<p style=\"text-align: justify;\">13.1.2.1. Clinical Studies<\/p>\n<p style=\"text-align: justify;\">13.1.3. Product Development Activities<\/p>\n<p style=\"text-align: justify;\">13.1.3.1. Collaboration<\/p>\n<p style=\"text-align: justify;\">13.1.3.2. Agreements<\/p>\n<p style=\"text-align: justify;\">13.1.3.3. Acquisition&nbsp;<\/p>\n<p style=\"text-align: justify;\">13.1.3.4. Patent Detail<\/p>\n<p style=\"text-align: justify;\">13.1.4. Tabulated Product Summary<\/p>\n<p style=\"text-align: justify;\">13.1.4.1. General Description Table<\/p>\n<p style=\"text-align: justify;\">14. Sjogren&#8217;s Syndrome&nbsp;Key Companies<\/p>\n<p style=\"text-align: justify;\">15. Sjogren&#8217;s Syndrome&nbsp;Key Products<\/p>\n<p style=\"text-align: justify;\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\">16.1. Dormant Products<\/p>\n<p style=\"text-align: justify;\">16.1.1. Reasons for being dormant<\/p>\n<p style=\"text-align: justify;\">16.2. Discontinued Products&nbsp;<\/p>\n<p style=\"text-align: justify;\">16.2.1. Reasons for the discontinuation<\/p>\n<p style=\"text-align: justify;\">17. Sjogren&#8217;s Syndrome&nbsp;Unmet Needs<\/p>\n<p style=\"text-align: justify;\">18. Sjogren&#8217;s Syndrome&nbsp;Future Perspectives<\/p>\n<p style=\"text-align: justify;\">19. Sjogren&#8217;s Syndrome&nbsp;Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\">21.1. Secondary Research<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">21.2. Expert Panel Validation&nbsp;<\/p>\n<p style=\"text-align: justify;\">VAY736 (Ianalumab) (Novartis\/MorphoSys) is a novel, subcutaneous, defucosylated, monoclonal antibody,&nbsp;that targets human B cell-activating factor (BAFF). It is engineered to prevent BAFF signaling and effectively&nbsp;eliminate B cells from circulation in vivo by antibody-dependent cellular cytotoxicity (ADCC), providing a&nbsp;dual mode of action. The molecule is being developed by the Novartis in partnership with MorphoSys as an antibody-based therapy. It is currently in Phase II clinical studies for the treatment of moderate to severe Primary Sj&ouml;gren&#8217;s Syndrome. The drug has met the primary endpoint assessing ESSDAI, showing statistically significant dose-response for Ianalumab with clinically important improvement in the results presented in 2019 ACR\/ARP Annual Meeting.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56407.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Priya Maurya<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=sjogrens-syndrome-pipeline-insights-2020\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=sjogrens-syndrome-pipeline-insights-2020\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Sjogren&#8217;s Syndrome Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Sjogren&#8217;s Syndrome market. A detailed picture of the Sjogren&#8217;s Syndrome pipeline landscape is provided, which includes the disease &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/sjogrens-syndrome-pipeline-insights-2020_496697.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-496697","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/496697","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=496697"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/496697\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=496697"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=496697"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=496697"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}